Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Induced Pluripotent Stem Cells Market Research Report Information By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons and Others), By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering and Cell Therapy), By End User (Research Institutions and Other End Users) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032


ID: MRFR/HC/20254-HCR | 128 Pages | Author: Rahul Gotadki| June 2024

Induced Pluripotent Stem Cells Market Segmentation


Induced Pluripotent Stem Cells Derived Cell Type Outlook (USD Billion, 2019-2032)




  • Hepatocytes




  • Fibroblasts




  • Keratinocytes




  • Neurons




  • Others




Induced Pluripotent Stem Cells Application Outlook (USD Billion, 2019-2032)




  • Drug Development




  • Regenerative Medicine




  • Toxicity Testing




  • Tissue Engineering




  • Cell Therapy




Induced Pluripotent Stem Cells End User Outlook (USD Billion, 2019-2032)




  • Research Institutions




  • Other End Users




Induced Pluripotent Stem Cells Regional Outlook (USD Billion, 2019-2032)




  • North America Outlook (USD Billion, 2019-2032)




    • North America Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • North America Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • North America Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • US Outlook (USD Billion, 2019-2032)




    • US Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • US Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • US Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • CANADA Outlook (USD Billion, 2019-2032)




    • CANADA Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • CANADA Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • CANADA Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users








  • Europe Outlook (USD Billion, 2019-2032)




    • Europe Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Europe Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Europe Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Germany Outlook (USD Billion, 2019-2032)




    • Germany Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Germany Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Germany Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • France Outlook (USD Billion, 2019-2032)




    • France Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • France Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • France Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • UK Outlook (USD Billion, 2019-2032)




    • UK Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • UK Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • UK Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • ITALY Outlook (USD Billion, 2019-2032)




    • ITALY Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • ITALY Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • ITALY Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • SPAIN Outlook (USD Billion, 2019-2032)




    • Spain Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Spain Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Spain Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Rest Of Europe Outlook (USD Billion, 2019-2032)




    • Rest Of Europe Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • REST OF EUROPE Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • REST OF EUROPE Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users








  • Asia-Pacific Outlook (USD Billion, 2019-2032)




    • Asia-Pacific Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Asia-Pacific Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Asia-Pacific Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • China Outlook (USD Billion, 2019-2032)




    • China Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • China Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • China Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Japan Outlook (USD Billion, 2019-2032)




    • Japan Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Japan Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Japan Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • India Outlook (USD Billion, 2019-2032)




    • India Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • India Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • India Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Australia Outlook (USD Billion, 2019-2032)




    • Australia Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Australia Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Australia Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)




    • Rest of Asia-Pacific Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Rest of Asia-Pacific Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Rest of Asia-Pacific Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users








  • Rest of the World Outlook (USD Billion, 2019-2032)




    • Rest of the World Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Rest of the World Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Rest of the World Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Middle East Outlook (USD Billion, 2019-2032)




    • Middle East Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Middle East Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Middle East Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Africa Outlook (USD Billion, 2019-2032)




    • Africa Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Africa Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Africa Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users






    • Latin America Outlook (USD Billion, 2019-2032)




    • Latin America Induced Pluripotent Stem Cells by Derived Cell Type




      • Hepatocytes




      • Fibroblasts




      • Keratinocytes




      • Neurons




      • Others






    • Latin America Induced Pluripotent Stem Cells by Application




      • Drug Development




      • Regenerative Medicine




      • Toxicity Testing




      • Tissue Engineering




      • Cell Therapy






    • Latin America Induced Pluripotent Stem Cells by End User




      • Research Institutions




      • Other End Users







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE

6.1. Overview

6.2. Hepatocytes

6.3. Fibroblasts

6.4. Keratinocytes

6.5. Neurons

6.6. Others

7. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION

7.1. Overview

7.2. Drug Development

7.3. Regenerative Medicine

7.4. Toxicity Testing

7.5. Tissue Engineering

7.6. Cell Therapy

8. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER

8.1. Overview

8.2. Research Institutions

8.3. Other End Users

9. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Induced Pluripotent Stem Cells Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Induced Pluripotent Stem Cells Market,

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2023

10.8.2. Major Players R&D Expenditure. 2023

11. COMPANY PROFILES

11.1. Fujifilm Cellular Dynamics International

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Thermo Fisher Scientific

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Merck KGaA

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. ReproCELL Inc.

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Takara Bio Inc.

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Lonza Group AG

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Stemgent

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Astellas Pharma Inc.

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Fate Therapeutics, Inc.

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Bristol Myers Squibb

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. GE Healthcare

11.11.1. Company Overview

11.11.2. Financial Overview

11.11.3. Products Offered

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 5 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 9 US: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 10 US: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 11 US: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 12 CANADA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 13 CANADA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 14 CANADA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 3 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 5 GERMANY: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 6 GERMANY: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 7 FRANCE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 8 FRANCE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 9 FRANCE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 10 ITALY: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 11 ITALY: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 12 ITALY: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 13 SPAIN: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 14 SPAIN: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 15 SPAIN: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 16 UK: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 17 UK: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 18 UK: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 25 JAPAN: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 26 JAPAN: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 27 JAPAN: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 28 CHINA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 29 CHINA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 30 CHINA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 31 INDIA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 32 INDIA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 33 INDIA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 34 AUSTRALIA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 35 AUSTRALIA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 36 AUSTRALIA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 49 AFRICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 50 AFRICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 51 AFRICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY DERIVED CELL TYPE, 2019-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 54 LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY END USER, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET

FIGURE 4 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY DERIVED CELL TYPE, 2023

FIGURE 5 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY APPLICATION, 2023

FIGURE 6 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY END USER, 2023

FIGURE 7 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 ASIA-PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 REST OF THE WORLD: INDUCED PLURIPOTENT STEM CELLS MARKET, SHARE (%), BY REGION, 2023

FIGURE 12 GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 13 FUJIFILM CELLULAR DYNAMICS INTERNATIONAL: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 FUJIFILM CELLULAR DYNAMICS INTERNATIONAL: SWOT ANALYSIS

FIGURE 15 THERMO FISHER SCIENTIFIC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 THERMO FISHER SCIENTIFIC: SWOT ANALYSIS

FIGURE 17 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 MERCK KGAA: SWOT ANALYSIS

FIGURE 19 REPROCELL INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 REPROCELL INC.: SWOT ANALYSIS

FIGURE 21 TAKARA BIO INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 TAKARA BIO INC.: SWOT ANALYSIS

FIGURE 23 LONZA GROUP AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 LONZA GROUP AG: SWOT ANALYSIS

FIGURE 25 STEMGENT: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 STEMGENT: SWOT ANALYSIS

FIGURE 27 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 ASTELLAS PHARMA INC.: SWOT ANALYSIS

FIGURE 29 FATE THERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 FATE THERAPEUTICS, INC.: SWOT ANALYSIS

FIGURE 31 BRISTOL MYERS SQUIBB: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 BRISTOL MYERS SQUIBB: SWOT ANALYSIS

FIGURE 33 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 GE HEALTHCARE: SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.